Program Schedule

1051
Well-child Visits and HPV Vaccination Rates in Privately Insured Females Aged 9-21 Years in the United States, 2007-2012

Session: Poster Abstract Session: Vaccines: HPV
Friday, October 10, 2014
Room: The Pennsylvania Convention Center: IDExpo Hall BC
Background: Well-child visits provide the best opportunities for vaccinations in the US. The Advisory Committee on Immunization Practices (ACIP) recommends vaccination of 11-12 year old preteens with Tdap (Tetanus, Diphtheria and Pertussis), Meningococcal Conjugate Vaccine (MCV4) and HPV (Human Papillomavirus) Vaccines. The objectives of this study was to understand utilization of well-child visits, estimate HPV vaccination rates during well-child visits, and compare HPV vaccination rates during well-child visits in 11-12 year girls with Tdap and MCV4 and with different vaccination rates in other age categories.

Methods: This was a retrospective database (MarketScan®) cohort study. Eligible subjects were 9-21 year old females who had continuous enrollment since June 1, 2006 or January 1 of the year when a child turned 9 years old, had well-child visits, and didn’t initiate HPV vaccine series previously. Vaccination rates for HPV during well-child visits were estimated and compared with Tdap and MCV4 for 11-12 year old females. Females who got the 1st dose of HPV vaccine during well-child visits were followed for two years to estimate HPV vaccine series completion rates. Descriptive and multivariate analyses were used in assessing the study’s objectives.   

Results: Well-child visits among 11-12 year old females were the highest (55.7% in 2012) and among ages 18-21 were the lowest (24.5%) (p<0.0001). As compared to 11-12 year olds, ages 13-15 were 24% less likely to come in for a well-child visit (p<0.0001). HPV vaccination rates during a well-child visit were similar in the 11-12 and 13-15 year age groups (19.0% and 21.1% in 2012). In 2012, HPV vaccination rates (19.0%) in 11-12 year old females during well-child visits were significantly lower than Tdap (33.7%) and MCV4 (32.0%) (p<0.0001). HPV vaccine three-dose series completion rates during a 2-year follow-up were 59.0% in 11-12 year old females and 49.1% in ages 13-15 for those who initiated the 1st dose during a well-child visit in 2010.

Conclusion: As determined from this claims analysis, 11-12 year old females are more likely to come in for a well-child visit and more likely to complete the HPV vaccine series compared to other age groups. Our analyses suggest that well-child visits at 11-12 years of age provide the best opportunity to maximize the potential of the HPV vaccination program in the US.

Dongmu Zhang, PHD, Global Health Outcomes, Merck & Co. Inc, West Point, PA, Nagesh N. Borse, PHD MS BSPHARM, Global Health Outcomes, Agile 1 - For Merck & Co., West Point, PA, Amit S. Kulkarni, PhD, Global Health Outcomes - Vaccine, Merck & Co. Inc, Whitehouse Station, NJ and Linda Niccolai, PhD ScM, Yale School of Public Health, Yale University, New Haven, CT

Disclosures:

D. Zhang, Merck: Employee, Salary

N. N. Borse, Merck: Consultant, Consulting fee

A. S. Kulkarni, Merck: Employee, Salary

L. Niccolai, Merck: Collaborator, Research Contractor and Scientific Advisor, Consulting fee

See more of: Vaccines: HPV
See more of: Poster Abstract Session
<< Previous Abstract | Next Abstract

Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

Sponsoring Societies:

© 2014, idweek.org. All Rights Reserved.

Follow IDWeek